BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

BioCryst Pharmaceuticals Inc BCRX announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE).

  • The results showed sustained reductions in attack rates and improved quality of life (QoL) among patients living with HAE, regardless of their baseline attack rates and initial responses to Orladeyo.
  • The analysis stratified all 21 patients by their initial reduction in HAE attack rate from baseline to Week 24 in three groups - Group A (<50 percent attack rate reduction; n=4), Group B (≥50 percent attack rate reduction; n=17), and Group C (≥70 percent attack rate reduction; n=14). 
  • Related: BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo.
  • A sustained reduction in HAE attack rates was observed from baseline to Week 96 across all three groups of patients. 
  • Group A had a mean decrease of 2.3 attacks/month, Group B had a mean decline of 2.5 attacks/month, and Group C had a mean reduction of 2.6 attacks/month.
  • At Week 96, median attack rates were 0.0 regardless of baseline attack rate.
  • Price Action: BCRX shares are down 2.77% at $16.24 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!